Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Assets (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Non-Current Assets for 12 consecutive years, with $131000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 88.14% to $131000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 42.98% year-over-year, with the annual reading at $131000.0 for FY2025, 88.14% down from the prior year.
  • Non-Current Assets hit $131000.0 in Q4 2025 for Viking Therapeutics, down from $712000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.7 million in Q1 2022 to a low of $131000.0 in Q4 2025.
  • Historically, Non-Current Assets has averaged $992400.0 across 5 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Non-Current Assets: soared 1011.19% in 2022 and later plummeted 88.14% in 2025.
  • Year by year, Non-Current Assets stood at $134000.0 in 2021, then skyrocketed by 1011.19% to $1.5 million in 2022, then dropped by 15.04% to $1.3 million in 2023, then decreased by 12.65% to $1.1 million in 2024, then tumbled by 88.14% to $131000.0 in 2025.
  • Business Quant data shows Non-Current Assets for VKTX at $131000.0 in Q4 2025, $712000.0 in Q3 2025, and $834000.0 in Q2 2025.